Tune in to see Professor Adnan Khattak present 2-year data from Evaxion’s phase 2 clinical trial in high-risk melanoma, and engage in discussing perspectives for bringing EVX-01 to patients. The webinar will take place on October 22 at 16:30 CEST / 10:30 EDT.
Many people die from cancer, drug-resistant bacteria and other infectious diseases. The demand for new and efficient drugs has never been higher, and will only keep on growing.
Every day, our AI platform, AI-Immunology™, brings us closer to a future where we can treat a wide range of critical diseases.
This is why our purpose is: Decoding the human immune system to develop novel vaccines for cancer and infectious diseases with our AI-Immunology™ platform.
Evaxion is a pioneering TechBio company with a leading AI–platform, AI-Immunology™, for fast and effective vaccine target discovery, design and development. AI-Immunology™ is clinically validated and can identify therapeutically relevant vaccine targets for cancer and infectious diseases.
AI-Immunology™ allows for ground-breaking development of novel personalized and precision vaccines for cancer and infectious diseases. The platform consists of a collection of unique in-house developed AI building blocks that can be intelligently combined to generate tailored AI prediction models addressing complex immune-related healthcare issues.
At Evaxion, we stand at the forefront of the biotechnology industry with our advanced use of artificial intelligence and machine learning technologies to model the immune system. However, our strength lies not only in our technological innovations but also in our comprehensive, multidisciplinary approach.
Our multidisciplinary team operates within state-of-the-art facilities to pioneer the design and development of personalized and precision vaccine candidates tailored to meet specific disease signatures and partners’ needs.
Our robust AI prediction models are specifically trained in the fields of cancer and infectious diseases, offering a clinically validated predictive capability that sets us apart in the biotech space. This precision allows for the rapid discovery of therapeutically relevant and delivery modality agnostic vaccine targets within 24 hours, enabling us to meet a wide range of specifications and requirements.
years of development
Initial Public Offering (IPO) on U.S. Nasdaq
personalized vaccine batches manufactured to date for clinical use
success rate on vaccine manufacturing for all enrolled patients where a vaccine could be designed
AI building blocks that can be ensembled into multiple different models
in-house developed assets between preclinical and phase 2
preclinical studies
patent families covering multiple inventions across AI-Immunology™ and pipeline assets
